SOLiD™ 3 Plus Enables Higher Throughput, Decreased Cost, and Faster
Data Analysis on Life Science Industry’s Most Accurate Sequencing
Platform
CARLSBAD, Calif.--(BUSINESS WIRE)--Oct. 21, 2009--
Applied Biosystems, part of Life Technologies Corporation (NASDAQ:LIFE)
today announced the commercial availability of the SOLiD™ 3 Plus System,
an enhanced next-generation genomic analysis platform designed to allow
researchers to move one step closer to performing mainstream sequencing
of personal genomes for clinical research and personalized medicine. The
technical enhancements to SOLiD 3 Plus include higher throughput,
decreased run costs, and faster data analysis which deliver on a roadmap
that enables scientists to sequence entire genomes in a more
cost-effective and easy manner.
The SOLiD 3 Plus System, distinguished by its unmatched accuracy, is
capable of generating more than 60 gigabases of mappable sequence data
per run, at a 20% lower cost per sequencing run than previously
possible. The combination of increased throughput, which equates to an
approximate 50% decrease in cost per gigabase, shorter run times, and
improved data analysis makes the SOLiD technology the ideal choice for
large-scale resequencing genomic projects.
An advanced software solution, BioScope™, has been introduced and
provides an integrated framework for data analysis, which allows
researchers to benefit from smaller data file sizes while delivering
faster mapping times. The addition of BioScope enables researchers to
export data into a standard base sequence format, enabling the
combination of data from multiple sequencing platforms into a single
project-based analysis, and allows direct comparison of data from
multiple next-generation sequencing platforms. This has proven to be
beneficial in large-scale genomic studies, such as the 1000 Genomes
Project.
Dr. Hans Lehrach, head of the Vertebrate Genomics Department at the Max
Planck Institute for Molecular Genetics, is currently utilizing four
SOLiD Systems for the 1000 Genomes Project and various other projects.
Dr. Lehrach’s work is focused on the fields of cancer genomics, genome
analysis and systems biology with particular interest in cellular and
molecular mechanisms of cancer and other diseases. His research team
currently uses the SOLiD System for a range of genomic studies,
including whole genome resequencing, methylation analysis, miRNA and
targeted resequencing.
Dr. Hans Lehrach, head of the Vertebrate Genomics Department at the
Max Planck Institute for Molecular Genetics
“In our view, next-generation sequencing is a key step to the future of
personalized medicine. Due to its high accuracy, and its relatively low
sequencing costs, the SOLiD platform is clearly a major contributor in
this development. The SOLiD 3 Plus technology in particular will enable
the targeted resequencing of larger sized panels of individuals,
especially in the field of cancer.”
Kip Miller, President, Genetic Systems Division at Life Technologies
“The delivery of these new performance attributes demonstrates Life
Technologies’ commitment to furthering innovation in advanced genomic
analysis technologies, and cements the SOLiD System as the most scalable
platform on the market. We believe the SOLiD System is the
next-generation sequencing technology platform of choice for a broad
range of advanced genomics research, including system biology and
disease studies.”
Supporting Resources
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology
tools company dedicated to improving the human condition. Our systems,
consumables and services enable researchers to accelerate scientific
exploration, driving to discoveries and developments that make life even
better. Life Technologies customers do their work across the biological
spectrum, working to advance personalized medicine, regenerative
science, molecular diagnostics, agricultural and environmental research,
and 21st century forensics. Life Technologies had sales of more than $3
billion in 2008, employs approximately 9,500 people, has a presence in
more than 100 countries, and possesses a rapidly growing intellectual
property estate of approximately 3,600 patents and exclusive licenses.
Life Technologies was created by the combination of Invitrogen
Corporation and Applied Biosystems Inc. For more information on how we
are making a difference please visit our website: www.lifetechnologies.com.
Follow Life Technologies on Twitter @LIFECorporation
Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about our
anticipated results that involve risks and uncertainties. Some of the
information contained in this press release, including, but not limited
to, statements as to industry trends and Life Technologies’ plans,
objectives, expectations and strategy for its business, contains
forward-looking statements that are subject to risks and uncertainties
that could cause actual results or events to differ materially from
those expressed or implied by such forward-looking statements. Any
statements that are not statements of historical fact are
forward-looking statements. When used, the words “believe,” “plan,”
“intend,” “anticipate,” “target,” “estimate,” “expect” and the like,
and/or future tense or conditional constructions (“will,” “may,”
“could,” “should,” etc.), or similar expressions, identify certain of
these forward-looking statements. Important factors which could cause
actual results to differ materially from those in the forward-looking
statements are detailed in filings made by Life Technologies with the
Securities and Exchange Commission. Life Technologies undertakes no
obligation to update or revise any such forward-looking statements to
reflect subsequent events or circumstances.
For Research Use Only. Not for use in diagnostic procedures.
Copyright 2009. Life Technologies Corporation. All rights reserved. AB
(Design), and Applied Biosystems are registered trademarks and SOLiD are
trademarks of Life Technologies or its subsidiaries in the United States
and/or certain other countries.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6078251&lang=en
Source: Life Technologies Corporation
Life Technologies
Lauren Lum, 650-638-6916
lauren.lum@lifetech.com
